Inhaled salbutamol from aerolizer and diskus at different inhalation flows, inhalation volume and number of inhalations in both healthy subjects and COPD patients

References

• Chrystyn H. The DiskusTM: a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61(6):1022–1036. doi:10.1111/j.1742-1241.2007.01382.x.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Niederlaender C. The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309–317. doi:10.1111/j.1742-1241.2011.02832.x.
   PubMed Web of Science ®Google Scholar
• Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today. 2000;3(7):246–256. doi:10.1016/S1461-5347(00)00275-3.
   PubMedGoogle Scholar
• Clark A, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110. doi:10.1089/jam.1993.6.99.
   PubMedGoogle Scholar
• Shur J, Harris H, Jones MD, Kaerger JS, Price R. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm Res. 2008;25(7):1631–1640. doi:10.1007/s11095-008-9538-y.
   PubMed Web of Science ®Google Scholar
• Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate. J Pharm Sci. 2010;99(8):3415–3429. doi:10.1002/jps.22100.
   PubMed Web of Science ®Google Scholar
• De Koning J, Van der Mark TW, Coenegracht P, Tromp TF, Frijlink H. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm. 2002;234(1-2):257–266.
   PubMedGoogle Scholar
• Chrystyn H, Price D. What you need to know about inhalers and how to use them. Prescriber 2009;20(12):47–52. doi:10.1002/psb.529.
   Google Scholar
• Chrystyn H, Corrado O, Brownlee K, et al. Inhalation rates of asthmatic children (CHILD) and adults and of chronic obstructive pulmonary disease (COPD) patients through inhalers. Am J Resp Crit Care Med 2002;165(8):A190.
   PubMedGoogle Scholar
• Pedersen S. How to use a rotahaler. Arch Dis Child. 1986;61(1):11–14. doi:10.1136/adc.61.1.11.
   PubMed Web of Science ®Google Scholar
• Abdelrahim ME. Emitted dose and lung deposition of inhaled terbutaline from Turbuhaler at different conditions. Respir Med. 2010;104(5):682–689. doi:10.1016/j.rmed.2009.11.014.
   PubMed Web of Science ®Google Scholar
• Ali AMA, Abdelrahim M. Modeling and optimization of terbutaline emitted from a dry powder inhaler and influence on systemic bioavailability using data mining technology. J Pharm Innov. 2014;9(1):38–47. doi:10.1007/s12247-014-9171-8.
   Web of Science ®Google Scholar
• Boshra MS, Almeldien AG, Salah Eldin R, et al. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers. Experimental Lung Research 2018;44(4-5):211–216.
   Web of Science ®Google Scholar
• Hassan A, Salah Eldin R, Abdelrahman MM, Abdelrahim ME. In-vitro/in-vivo comparison of inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during non-invasive ventilation. Exp Lung Res. 2017;43(1):19–28. doi:10.1080/01902148.2017.1282993.
   PubMed Web of Science ®Google Scholar
• Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]. Br J Clin Pharmacol. 1992;34(4):311–315. doi:10.1111/j.1365-2125.1992.tb05921.x.
   PubMed Web of Science ®Google Scholar
• Silkstone V, Dennis J, Pieron C, Chrystyn H. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J Aerosol Med. 2002;15(3):251–259. doi:10.1089/089426802760292591.
   PubMedGoogle Scholar
• Skaria S, Smaldone GC. Omron NE U22: comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv. 2010;23(3):173–180. doi:10.1089/jamp.2010.0817.
   PubMed Web of Science ®Google Scholar
• Abdelrahim ME, Assi KH, Chrystyn H. Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion. Br J Clin Pharmacol. 2011;71(4):608–610. doi:10.1111/j.1365-2125.2010.03873.x.
   PubMed Web of Science ®Google Scholar
• Moustafa IO, Ali M-A, Al Hallag M, et al. Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients. Heart & Lung: The Journal of Acute and Critical Care. 2017;46(6):464–467. doi:10.1016/j.hrtlng.2017.08.004.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MM. Solid-Phase Extraction and HPLC-DAD for Determination of Salbutamol in Urine Samples. Anal Chem Lett. 2018;8(1):35–45. doi:10.1080/22297928.2017.1396918.
   Google Scholar
• Hussein RR, Ma Ali A, Salem HF, Abdelrahman MM, Said AS, Abdelrahim ME. In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients. Pharm Dev Technol. 2017;22(7):871–880. doi:10.3109/10837450.2015.1116567.
   PubMed Web of Science ®Google Scholar
• Hassan A, Rabea H, Hussein RR, et al. In-vitro characterization of the aerosolized dose during non-invasive automatic continuous positive airway pressure ventilation. Pulm Ther. 2016;2(1):115–126. doi:10.1007/s41030-015-0010-y.
   Google Scholar
• Rabea H, Ali AM, Eldin RS, Abdelrahman MM, Said AS, Abdelrahim ME. Modelling of in-vitro and in-vivo performance of aerosol emitted from different vibrating mesh nebulisers in non-invasive ventilation circuit. Eur J Pharm Sci. 2017;97:182–191. doi:10.1016/j.ejps.2016.11.018.
   PubMed Web of Science ®Google Scholar
• Abdelrahim M, Assi K, Chrystyn H. Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow. Pharm Dev Technol. 2013;18(4):944–949. doi:10.3109/10837450.2011.620970.
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann AmThoracic Soc 2017;14(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respiratory Soc 2011;37(6):1308–1331.
   PubMed Web of Science ®Google Scholar
• Hawksworth G, James L, Chrystyn H. Characterization of the inspiratory manoeuvre when asthmatics inhale through a Turbohaler pre-and post-counselling in a community pharmacy. Resp Med. 2000;94(5):501–504. doi:10.1053/rmed.1999.0768.
   PubMed Web of Science ®Google Scholar
• Kamin W, Genz T, Roeder S, et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J Aerosol Med. 2002;15(1):65–73. doi:10.1089/08942680252908593.
   PubMedGoogle Scholar
• Azouza W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Primary Care Resp J. 2012;21(2):208. doi:10.4104/pcrj.2012.00010.
   PubMedGoogle Scholar
• Azouz W, Chetcuti P, Hosker HS, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med PulmDrug Delivery. 2015;28(1):35–42. doi:10.1089/jamp.2013.1119.
   PubMed Web of Science ®Google Scholar
• Saeed H, Salem HF, Rabea H, Abdelrahim ME. Effect of Human Error, Inhalation Flow, and Inhalation Volume on Dose Delivery from Ellipta® Dry-Powder Inhaler. J Pharm Innov 2018;:1–6.
   Web of Science ®Google Scholar
• Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in‐check dial device to simulate low‐resistance (Diskus) and high‐resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol. 2005;39(5):447–451. doi:10.1002/ppul.20180.
   PubMed Web of Science ®Google Scholar
• Madney YM, Fathy M, Elberry AA, et al. Abstracts: International Society for Aerosols in Medicine eV 21st ISAM Congress Santa Fe, NM June 3–7, 2017. J Aerosol Med Pulm Drug Delivery 2017;30(3):A-1–A-38.
   PubMedGoogle Scholar
• Nicola M, Elberry AA, Sayed OM, Hussein RR, Abdelrahim ME. Effect of DPI's training-device on inhalation technique and clinical efficacy in asthmatics. Beni-Suef Univ J Basic Appl Sci. 2018;7(2):178–183. doi:10.1016/j.bjbas.2017.10.005.
   Google Scholar
• Elgendy MO, Abdelrahim ME, Eldin RS. Potential benefit of repeated dry powder inhaler’s inhalation technique counseling on asthmatic patients. Pulm Ther. 2015;1(1):91–101. doi:10.1007/s41030-015-0004-9.
   Google Scholar
• Lipworth B, Clark D. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax 1997 December 1, 1997;52(12):1036–1039. doi:10.1136/thx.52.12.1036.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032–1045. doi:10.1016/S0140-6736(10)60926-9.
   PubMed Web of Science ®Google Scholar
• Abadelah M, Chrystyn H, Bagherisadeghi G, Abdalla G, Larhrib H. Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg. AAPS Pharm Sci Tech. 2018;19(1):251–261. doi:10.1208/s12249-017-0841-y.
   PubMed Web of Science ®Google Scholar
• Meyer T, Brand P, Ehlich H, et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med. 2004;17(1):43–49. doi:10.1089/089426804322994451.
   PubMedGoogle Scholar